Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-EBTATE
- Development stage
- Unknown
- Lead developer
- Molecular Targeting Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
225Ac-EBTATE is a targeted radiopharmaceutical developed by Molecular Targeting Technologies, Inc. (MTTI) for the treatment of somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) and small cell lung cancer (SCLC). The drug consists of the alpha-emitting radioisotope actinium-225 conjugated to a somatostatin analogue (TATE) via an Evans Blue (EB) moiety. This EB technology platform allows the drug to bind reversibly to endogenous serum albumin, significantly extending its circulatory half-life and increasing tumor residence time. Preclinical studies have shown that 225Ac-EBTATE achieves significantly higher tumor uptake and anti-tumor efficacy compared to standard 225Ac-DOTATATE, potentially allowing for effective treatment at lower doses. The drug is scheduled to enter Phase 1/2 clinical trials in 2025.
- Brand names
- 225Ac-EBTATE
- Other names
- 225Ac-EB-DOTATATE225Ac-Evans Blue-DOTATATE
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on 225Ac-EBTATE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-EBTATE.